1189703-33-0
1189703-33-0
Chemical Structure
Ethosuximide-d3
- CAS No.: 1189703-33-0
- Formula:C7H8D3NO2
- Molecular Weight:144.19
IUPAC Name: 3-(ethyl-2,2,2-d3)-3-methylpyrrolidine-2,5-dione
InChIKey: HAPOVYFOVVWLRS-FIBGUPNXSA-N
SMILES: C(C([2H])([2H])[2H])C1(C)C(=O)NC(=O)C1
Biological Activity: Ethosuximide-d3 is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ethosuximide-d3 | Ethosuximide-d3 is the deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethosuximide (Standard) | ≥98% | Ethosuximide (Standard) is the analytical standard of Ethosuximide. This product is intended for research and analytical applications. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethosuximide-13C, d3 | Ethosuximide-13C, d3 is the 13C- and deuterium labeled Ethosuximide (HY-B1378). Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethosuximide-d5 | Ethosuximide-d5 is deuterium labeled Ethosuximide. Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ethosuximide | 99.35% | Ethosuximide, a widely prescribed anti-epileptic agent, improves the phenotypes of multiple neurodegenerative disease models and blocks the low voltage activated T-type calcium channel. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Chen X, et al. Ethosuximide ameliorates neurodegenerative disease phenotypes by modulating DAF-16/FOXO target gene expression. Mol Neurodegener. 2015 Sep 29;10:51. [Content Brief]
